Repligen | RGEN - Capital Ordinário





Capital Ordinário Alterar Data
Agilent USD 281.97M 252K 2026-06
Align Technology USD 71.62M 1000 2026-06
Bio Techne USD 156.45M 703K 2026-03
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Bruker USD 152.35M 130K 2026-06
Charles River Laboratories USD 47.73M 439K 2026-06
Danaher USD 703.4M 500K 2026-09
Dentsply International USD 199.2M 1.1M 2026-06
General Electric Aerospace USD 1.03B 4.21M 2026-09
Henry Schein USD 111.92M 2.51M 2026-06
Illumina USD 151.3M 607K 2026-06
IQVIA Holdings USD 164.6M 2.3M 2026-06
Mettler Toledo International USD 20.21M 40.9K 2026-06
Myriad Genetics USD 93.5M 400K 2025-12
OraSure Technologies USD 70.39M 1.87M 2025-12
Pacific Biosciences Of California USD 301.96M 103K 2025-12
Pfizer USD 5.7B 0 2026-06
Repligen USD 56.43M 28K 2026-06
Revvity USD 111.63M 174K 2026-06
Standard Biotools USD 390.14M 3.76M 2026-03
Thermo Fisher Scientific USD 369.75M 1.88M 2026-09
Waters USD 98.19M 20K 2026-06
West Pharmaceutical Services USD 70.4M 500K 2026-06